These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1278 related items for PubMed ID: 30324273

  • 1. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
    Hwang HW, Jung H, Hyeon J, Park YH, Ahn JS, Im YH, Nam SJ, Kim SW, Lee JE, Yu JH, Lee SK, Choi M, Cho SY, Cho EY.
    Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
    [Abstract] [Full Text] [Related]

  • 2. Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers.
    Watanabe T, Hida AI, Inoue N, Imamura M, Fujimoto Y, Akazawa K, Hirota S, Miyoshi Y.
    Breast Cancer Res Treat; 2018 Feb; 168(1):135-145. PubMed ID: 29168063
    [Abstract] [Full Text] [Related]

  • 3. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
    Ochi T, Bianchini G, Ando M, Nozaki F, Kobayashi D, Criscitiello C, Curigliano G, Iwamoto T, Niikura N, Takei H, Yoshida A, Takei J, Suzuki K, Yamauchi H, Hayashi N.
    Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
    [Abstract] [Full Text] [Related]

  • 4. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade.
    Nuciforo P, Pascual T, Cortés J, Llombart-Cussac A, Fasani R, Paré L, Oliveira M, Galvan P, Martínez N, Bermejo B, Vidal M, Pernas S, López R, Muñoz M, Garau I, Manso L, Alarcón J, Martínez E, Rodrik-Outmezguine V, Brase JC, Villagrasa P, Prat A, Holgado E.
    Ann Oncol; 2018 Jan 01; 29(1):170-177. PubMed ID: 29045543
    [Abstract] [Full Text] [Related]

  • 5. Imaging and Clinicopathologic Features Associated With Pathologic Complete Response in HER2-positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Dual HER2 Blockade.
    Yoon GY, Chae EY, Cha JH, Shin HJ, Choi WJ, Kim HH, Kim JE, Kim SB.
    Clin Breast Cancer; 2020 Feb 01; 20(1):25-32. PubMed ID: 31519449
    [Abstract] [Full Text] [Related]

  • 6. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R, Denkert C, Campbell C, Savas P, Nuciforo P, Aura C, de Azambuja E, Eidtmann H, Ellis CE, Baselga J, Piccart-Gebhart MJ, Michiels S, Bradbury I, Sotiriou C, Loi S.
    JAMA Oncol; 2015 Jul 01; 1(4):448-54. PubMed ID: 26181252
    [Abstract] [Full Text] [Related]

  • 7. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
    Asano Y, Kashiwagi S, Goto W, Takada K, Takahashi K, Hatano T, Takashima T, Tomita S, Motomura H, Ohsawa M, Hirakawa K, Ohira M.
    Anticancer Res; 2018 Apr 01; 38(4):2311-2321. PubMed ID: 29599354
    [Abstract] [Full Text] [Related]

  • 8. Tumor-infiltrating lymphocytes affect the efficacy of trastuzumab-based treatment in human epidermal growth factor receptor 2-positive breast cancer.
    Inoue H, Horii R, Ito Y, Iwase T, Ohno S, Akiyama F.
    Breast Cancer; 2018 May 01; 25(3):268-274. PubMed ID: 29185202
    [Abstract] [Full Text] [Related]

  • 9. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
    Liu S, Duan X, Xu L, Xin L, Cheng Y, Liu Q, Ye J, Zhang S, Zhang H, Zhu S, Li T, Liu Y.
    Breast Cancer Res Treat; 2015 Nov 01; 154(2):239-49. PubMed ID: 26498019
    [Abstract] [Full Text] [Related]

  • 10. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, Budczies J, Huober J, Klauschen F, Furlanetto J, Schmitt WD, Blohmer JU, Karn T, Pfitzner BM, Kümmel S, Engels K, Schneeweiss A, Hartmann A, Noske A, Fasching PA, Jackisch C, van Mackelenbergh M, Sinn P, Schem C, Hanusch C, Untch M, Loibl S.
    Lancet Oncol; 2018 Jan 01; 19(1):40-50. PubMed ID: 29233559
    [Abstract] [Full Text] [Related]

  • 11. Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.
    Meisel JL, Zhao J, Suo A, Zhang C, Wei Z, Taylor C, Aneja R, Krishnamurti U, Li Z, Nahta R, O'Regan R, Li X.
    Clin Breast Cancer; 2020 Feb 01; 20(1):19-24. PubMed ID: 31806448
    [Abstract] [Full Text] [Related]

  • 12. On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer.
    Sinn BV, Sychra K, Untch M, Karn T, van Mackelenbergh M, Huober J, Schmitt W, Marmé F, Schem C, Solbach C, Stickeler E, Tesch H, Fasching PA, Schneeweiss A, Müller V, Holtschmidt J, Nekljudova V, Loibl S, Denkert C.
    Breast Cancer Res; 2024 Sep 24; 26(1):138. PubMed ID: 39317942
    [Abstract] [Full Text] [Related]

  • 13. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
    Luen SJ, Salgado R, Fox S, Savas P, Eng-Wong J, Clark E, Kiermaier A, Swain SM, Baselga J, Michiels S, Loi S.
    Lancet Oncol; 2017 Jan 24; 18(1):52-62. PubMed ID: 27964843
    [Abstract] [Full Text] [Related]

  • 14. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
    Schlotter CM, Tietze L, Vogt U, Heinsen CV, Hahn A.
    Horm Mol Biol Clin Investig; 2017 Sep 22; 32(2):. PubMed ID: 28937963
    [Abstract] [Full Text] [Related]

  • 15. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
    Luen SJ, Salgado R, Dieci MV, Vingiani A, Curigliano G, Gould RE, Castaneda C, D'Alfonso T, Sanchez J, Cheng E, Andreopoulou E, Castillo M, Adams S, Demaria S, Symmans WF, Michiels S, Loi S.
    Ann Oncol; 2019 Feb 01; 30(2):236-242. PubMed ID: 30590484
    [Abstract] [Full Text] [Related]

  • 16. Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China.
    Guan D, Jie Q, Wu Y, Xu Y, Hong W, Meng X.
    World J Surg Oncol; 2022 Sep 29; 20(1):326. PubMed ID: 36175898
    [Abstract] [Full Text] [Related]

  • 17. Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials.
    Solinas C, Ceppi M, Lambertini M, Scartozzi M, Buisseret L, Garaud S, Fumagalli D, de Azambuja E, Salgado R, Sotiriou C, Willard-Gallo K, Ignatiadis M.
    Cancer Treat Rev; 2017 Jun 29; 57():8-15. PubMed ID: 28525810
    [Abstract] [Full Text] [Related]

  • 18. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.
    Mao Y, Qu Q, Zhang Y, Liu J, Chen X, Shen K.
    PLoS One; 2014 Jun 29; 9(12):e115103. PubMed ID: 25501357
    [Abstract] [Full Text] [Related]

  • 19. Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.
    Asano Y, Kashiwagi S, Goto W, Takada K, Takahashi K, Hatano T, Noda S, Takashima T, Onoda N, Tomita S, Motomura H, Ohsawa M, Hirakawa K, Ohira M.
    BMC Cancer; 2017 Dec 28; 17(1):888. PubMed ID: 29282021
    [Abstract] [Full Text] [Related]

  • 20. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
    Lundgren C, Bendahl PO, Ekholm M, Fernö M, Forsare C, Krüger U, Nordenskjöld B, Stål O, Rydén L.
    Breast Cancer Res; 2020 Dec 23; 22(1):140. PubMed ID: 33357231
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.